The cell-free DNA (cfDNA) blood collection tube market is ripe with opportunities driven by the rise in lifestyle-related ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand ...

Natera Inc. is conducting a study titled ‘EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND).’ The study aims to develop and validate a single-gene Non-Invasive Prenatal ...

Researchers developed a cell-free DNA blood test that accurately distinguishes ALS from other neurological diseases and tracks progression.

Founded by Dr. Thomas Crisman, Genome Based Diagnostics has focused on developing accessible and reliable testing solutions ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced another successful readout for its ECD program, which is evaluating a blood-based screening test ...

A major US study reveals that marijuana use leaves measurable chemical traces in DNA, altering genes related to mental health ...

A label-free nanopore platform uses programmable DNA circuits to build versatile molecular logic gates, forming a universal basis for scalable DNA computing and advanced biosensing applications.

The partner firm has used 4basebio's template to develop an mRNA product which has been tested on patients in phase-one and two clinical trials, following investigational new drug approval from the US ...

Insight Molecular Diagnostics Inc. (($IMDX)) announced an update on their ongoing clinical study. Study Overview: The GraftAssureDx Study, ...

Considering pregnancy later in life? Find out what “advanced maternal age” really means, the risks to consider and how women ...

In a promising advance for cancer treatment, Northwestern University scientists have re-engineered the molecular structure of ...